Designing CD4 immunoadhesins for AIDS therapy
1989
Abstract
A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.
Details
Title
Designing CD4 immunoadhesins for AIDS therapy
Author(s)
Capon, D. J. ; Chamow, S. M. ; Mordenti, J. ; Marsters, S. A. ; Gregory, T. ; Mitsuya, H. ; Byrn, R. A. ; Lucas, C. ; Wurm, F. M. ; Groopman, J. E.
Published in
Nature
Volume
337
Issue
6207
Pages
525-31
Date
1989
ISSN
0028-0836
Keywords
Acquired Immunodeficiency Syndrome/immunology/metabolism/*therapy; Adjuvants; Immunologic/*chemical synthesis/metabolism/pharmacokinetics; Animals; Antigens; Surface/administration & dosage/chemical synthesis/*immunology; Binding Sites; Antibody; Binding; Competitive; Cell Adhesion Molecules; Cell Line; Drug Design; HIV Envelope Protein gp120; Half-Life; Humans; *Immunoglobulin G/administration & dosage/metabolism; Mice; Rabbits; Receptors; Complement/analysis; Receptors; Fc/analysis; Receptors; HIV; Receptors; Virus/administration & dosage/*immunology; Retroviridae Proteins/metabolism
Note
Department of Molecular Biology, Genentech, Inc., South San Francisco, California 94080.
Other identifier(s)
View record in PubMed
Laboratories
LBTC
Record Appears in
Scientific production and competences > SV - School of Life Sciences > SV Archives > LBTC - Cellular Biotechnology Laboratory
Peer-reviewed publications
Work produced at EPFL
Journal Articles
Published
Peer-reviewed publications
Work produced at EPFL
Journal Articles
Published
Record creation date
2007-06-05